Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olendalizumab - Alexion AstraZeneca Rare Disease

Next Previous
Drug Profile

Olendalizumab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN-1007

Latest Information Update: 27 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease
  • Class Anti-inflammatories; Antibodies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Antiphospholipid syndrome; Graft-versus-host disease; Inflammation

Most Recent Events

  • 27 Sep 2021 Discontinued - Phase-I for Inflammation (In volunteers) in USA (IV) (Alexion pipeline and straZeneca pipeline, September 2021)
  • 27 Sep 2021 Discontinued - Phase-II for Antiphospholipid syndrome in France, Brazil, USA, Japan, United Kingdom, Spain, Italy (IV) (Alexion pipeline and straZeneca pipeline, September 2021)
  • 27 Sep 2021 Discontinued - Phase-II for Graft-versus-host disease (Newly diagnosed) in USA, France (IV) (Alexion pipeline and straZeneca pipeline, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top